
Personalis, Inc. is a genomic diagnostics and data-analysis company focused on precision oncology and population genomics. Its current offerings include advanced sequencing tests that characterize tumors and immune-system interactions, supporting cancer diagnosis, treatment selection, disease monitoring, and pharmaceutical research. The company provides products such as ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which are designed to generate detailed genomic and immunologic insights from patient samples. Personalis, Inc. also delivers sequencing and analytical services for biopharmaceutical organizations developing cancer therapies, including personalized vaccines and immunotherapies, as well as for large-scale population sequencing initiatives. Its capabilities combine laboratory testing, bioinformatics, and data interpretation to help researchers and healthcare professionals understand disease biology and treatment response. Headquartered in Fremont, California, Personalis, Inc. serves the growing precision-medicine market by connecting high-resolution genomic information with clinical and drug-development applications.
www.personalis.com